2022•American Journal of Ophthalmology Case ReportsOpen access

Delayed and reversible ethambutol optic neuropathy

Elizabeth A. Peterson, Eman Hawy

Open full text 4 citations

Abstract

Purpose: To document an unusual example of ethambutol optic neuropathy developing three years from treatment start date in the absence of renal dysfunction. Observations: , presented with visual acuity that was significantly worse than baseline three years after beginning a treatment regimen which included ethambutol at <15 mg/kg/day. He was also found to have central and paracentral scotomas in both eyes. Ethambutol treatment was immediately halted, and the patient's visual acuity and visual fields improved in the months following. Conclusions and Importance: It is important to have a high index of suspicion for ethambutol toxicity in any patient on this drug who presents with vision changes consistent with optic neuropathy. The development of ethambutol optic neuropathy can be delayed, and vision loss may be reversible and can continue to improve over months after cessation of therapy.

Open-access reader

About this research paper

What this paper is about

Purpose: To document an unusual example of ethambutol optic neuropathy developing three years from treatment start date in the absence of renal dysfunction. Observations: , presented with visual acuity that was significantly worse than baseline three years after beginning a treatment regimen which included ethambutol at <15 mg/kg/day. He was also found to have central and paracentral scotomas in both eyes. Ethambutol treatment was immediately halted, and the patient's visual acuity and visual fields improved in the months following. Conclusions and Importance: It is important to have a high index of suspicion for ethambutol toxicity in any patient on this drug who presents with vision changes consistent with optic neuropathy. The development of ethambutol optic neuropathy can be delayed, and vision loss may be reversible and can continue to improve over months after cessation of therapy.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Purpose: To document an unusual example of ethambutol optic neuropathy developing three years from treatment start date in the absence of renal dysfunction. Observations: , presented with visual acuity that was significantly worse than baseline three years after beginning a treatment regimen which included ethambutol at <15 mg/kg/day. He was also found to have central and paracentral scotomas in both eyes. Ethambutol treatment was immediately halted, and the patient's visual acuity and visual fields improved in the months following. Conclusions and Importance: It is important to have a high index of suspicion for ethambutol toxicity in any patient on this drug who presents with vision changes consistent with optic neuropathy. The development of ethambutol optic neuropathy can be delayed, and vision loss may be reversible and can continue to improve over months after cessation of therapy.

Key concepts: Ethambutol, Optic neuropathy, Medicine, Visual acuity, Ophthalmology, Regimen, Surgery, Optic nerve

Related papers

Back to paper searchBrowse research topicsOriginal source
Delayed and reversible ethambutol optic neuropathy — Research Paper | ScholarLens